News | June 03, 2022
GSK to acquire clinical-stage biopharmaceutical company Affinivax for US$ 3.3 billion
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
If granted, Nuvaxovid would be the first protein-based Covid-19 vaccine option for adolescents in Australia and New Zealand
Covaxin was earlier approved for children 12-18 years of age
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
This could be a game-changer for the prevention of the disease; seeing more doses of the life-saving jab reach more girls
Collaboration awarded €3 million grant by the Bill & Melinda Gates Foundation
Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
Subscribe To Our Newsletter & Stay Updated
